UbrelvyArticle
Comparing Acute Migraine Treatment Options: Clinical Considerations for CGRP Receptor Antagonists
Both ubrogepant and rimegepant are FDA-approved CGRP receptor antagonists for acute migraine treatment
All topics
Ubrelvy
3 publications
UbrelvyWebpage
Comparing Ubrelvy and Nurtec ODT: Understanding the Differences in Migraine Treatment
Nurtec ODT has dual approval for acute treatment and prevention, while Ubrelvy is approved only for acute treatment
UbrelvyWebpage
Understanding Most Bothersome Symptom Relief in Migraine Treatment Studies
Most bothersome symptom (MBS) freedom measures relief from a patient's self-identified most troubling migraine symptom beyond headache pain